The FluoroPharma Medical, Inc. (FPMI) Business Strategy
FluoroPharma Medical intends to lead in the discovery, development, and commercialization of innovative and targeted molecular imaging pharmaceuticals that improve disease detection, management, and overall patient care. The company’s focus has been chemical tracer agents that are used in conjunction with positron emission tomography (PET), allowing PET scans to detect various biological processes occurring deep within the body. Such detection is valuable for identifying potential early stage disease, as well as being a tool for researchers. Specific steps the company is taking or planning to take include the following: • Seek regulatory approval in the U.S. and other countries for…